Key takeaways
Dovato (dolutegravir/lamivudine) and Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) are both first-choice treatments for HIV, but they have some key differences. Dovato combines two antiretrovirals (ARVs) into one pill, while Biktarvy combines three ARVs. This means Dovato has fewer medications in its regimen compared to Biktarvy. Dovato is not recommended for people with both HIV and hepatitis B, whereas Biktarvy contains tenofovir, which is also a first-choice treatment for hepatitis B. Both medications are taken once daily and can be taken with or without food, but they have different side effect profiles. Common side effects of Dovato include headache and weight gain, while Biktarvy commonly causes diarrhea, nausea, and headache. Additionally, Dovato has a known risk of causing neural tube defects if taken during the first trimester of pregnancy, whereas there is not enough data to confirm the safety of Biktarvy during pregnancy. Both medications require careful management of drug interactions, especially with antacids and certain other medications.
